Table 1:
Demographics Across All CASIRE Sites
| Age Group (N=868) | N | % | |||
|---|---|---|---|---|---|
| Pediatric (<18 y/o) | 443 | 51 | |||
| Adult (≥ 18 y/o) | 425 | 49 | |||
| Country (N=868) | |||||
| US | 245 | 28.1 | |||
| Italy | 81 | 9.4 | |||
| UK | 177 | 20.4 | |||
| Ghana | 365 | 42.1 | |||
| Gender (N=868) | |||||
| Female | 448 | 51.6 | |||
| Male | 420 | 48.4 | |||
| Genotype (N=868) | |||||
| HgbSS or HgbSS with Alpha Thal Trait | 656 | 75.6 | |||
| HgbSC | 162 | 18.7 | |||
| HgbSBeta+ | 28 | 3.2 | |||
| HgbSBeta0 | 22 | 2.5 | |||
| Disease Modifying therapies by Country* | |||||
| Country | Hydroxyurea (N=867) | Country | Chronic Blood Transfusion (N=867) | ||
|---|---|---|---|---|---|
| Yes | No | Yes | No | ||
| N (%) | N (%) | N (%) | N (%) | ||
| US (N=245) | 108(44.1) | 137(55.9) | US | 53(21.6) | 192(78.4) |
| Italy(N=81) | 18(22.2) | 63(77.8) | Italy | 15(18.5) | 66(81.5) |
| UK (N=176) | 45(25.6) | 131(74.4) | UK | 25(14.2) | 151(85.8) |
| Ghana (N=365) | 10(2.7) | 355(97.3) | Ghana | 0(0) | 365(100) |
*
20 patients were on both hydroxyurea and chronic transfusion therapy